Ambow Education Holding (AMBO), which provides education, test prep and IT career training services in China, plans to raise $117 million by offering 10,677,210 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, Ambow Education Holding will command a market value of $844.24 million. Ambow Education Holding, which was founded in 2000, booked $146 million in sales over the last 12 months. The Beijing, China-based company plans to list on the NYSE under the symbol AMBO. J.P. Morgan (JPM), Goldman Sachs (Asia) L.L.C. (GS) are the lead underwriters on the deal.

D. Medical (DMED), a medical device company that develops and manufactures insulin pumps, plans to raise $30 million by offering 2,727,273 at a price range of $10.00 to $12.00. At the mid-point of the proposed range, D. Medical will command a market value of $98.33 million. D. Medical, which was founded in 1992, booked $0 million in sales over the last 12 months. The Ramat Gan, Israel-based company plans to list on the NASDAQ under the symbol DMED. Rodman & Renshaw (RODM), ThinkEquity are the lead underwriters on the deal.

Gordmans Stores (GMAN), an everyday low price fashion retailer operating 68 stores in the Midwest, plans to raise $75 million by offering 5,357,143 at a price range of $13.00 to $15.00. At the mid-point of the proposed range, Gordmans Stores will command a market value of $261.84 million. Gordmans Stores, which was founded in 1915, booked $458 million in sales over the last 12 months. The Omaha, NE-based company plans to list on the NASDAQ under the symbol GMAN. Piper Jaffray (PJC), Wells Fargo Securities (WFC) are the lead underwriters on the deal.

IntraLinks Holdings (IL), which provides secure online document management to over 4,300 customers, plans to raise $165 million by offering 11,000,000 at a price range of $14.00 to $16.00. At the mid-point of the proposed range, IntraLinks Holdings will command a market value of $766.70 million. IntraLinks Holdings, which was founded in 1996, booked $141 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol IL. Morgan Stanley (MS), Deutsche Bank Securities (DB), and Credit Suisse (CS) are the lead underwriters on the deal.

NuPathe (PATH), a specialty pharma seeking approval for Zelrix, a patch for migraine treatment, plans to raise $75 million by offering 5,000,000 at a price range of $14.00 to $16.00. At the mid-point of the proposed range, NuPathe will command a market value of $211.68 million. NuPathe, which was founded in 2005, booked $0 million in sales over the last 12 months. The Conshohocken, PA-based company plans to list on the NASDAQ under the symbol PATH. Leerink Swann, Lazard Capital Markets (LAZ) are the lead underwriters on the deal.

NXP Semiconductors (NXPI), a diversified global semiconductor company and former carve-out of Philips, plans to raise $663 million by offering 34,000,000 at a price range of $18.00 to $21.00. At the mid-point of the proposed range, NXP Semiconductors will command a market value of $4,860.40 million. NXP Semiconductors, which was founded in 1953, booked $3,843 million in sales over the last 12 months. The Eindhoven, Netherlands-based company plans to list on the NASDAQ under the symbol NXPI. Credit Suisse, Goldman, Sachs & Co., and Morgan Stanley are the lead underwriters on the deal. Please note: *Filed with SEC under KASLION Acquisition B.V.

SurgiVision (SRGV), which has developed an MRI-guided device for minimally invasive brain procedures, plans to raise $25 million by offering 2,500,000 at a price range of $13.00 to $15.00. At the mid-point of the proposed range, SurgiVision will command a market value of $111.01 million. SurgiVision, which was founded in 1998, booked $3 million in sales over the last 12 months. The Memphis, TN-based company plans to list on the NASDAQ under the symbol SRGV. Canaccord Genuity (CCDPF.PK), Rodman & Renshaw are the lead underwriters on the deal. Please note: *Lowered range to $9-$11 (was $13-$15) [Update: IPO is now postponed.]

Trius Therapeutics (TSRX), which is developing an antibiotic for serious gram-positive Staph infections, plans to raise $78 million by offering 6,000,000 at a price range of $12.00 to $14.00. At the mid-point of the proposed range, Trius Therapeutics will command a market value of $216.82 million. Trius Therapeutics, which was founded in 2004, booked $5 million in sales over the last 12 months. The San Diego, CA-based company plans to list on the NASDAQ under the symbol TSRX. Citi (C), Piper Jaffray, and Canaccord Genuity are the lead underwriters on the deal. Please note: *Previously postponed on 3/1/2010 due to modification of its Ph. 3 trials, refiled amendment on 6/16/2010.

Last week, there were 3 IPO pricings. Envestnet (ENV), which provides outsourced web-based investment solutions to financial advisors, was the week’s winner, ending up 12% from its IPO price.

As always we will post our latest stock, IPO information and links on Twitter and will provide our weekly commentary through newsletter so don’t wait to sign up and join over 19k satisfied readers while it still FREE.

A scan for due diligence revealed the following information: 

I’ve seen that the market is quite short-sighted and will often bid a stock to lofty levels based on one or two good years. Based on the current situation, I believe that a company earning over $4 TTM and still making major moves to grow should not be valued under $20. Its stock is mispriced in the short-term, likely caused by the 35 day slump in the BDI. 

Longer term, an eventual recovery should see GNK exceeding the $4.73 EPS from 2009, especially with 30% more tonnage capacity in the future. If GNK can pull off $5 in full year earnings in 2012 or 2013 and the market assigns a multiple of only 7, that’s more than a double from current levels. Assigning a multiple of 7 to TTM earnings of $4.48 gives us a value of $31.36 per share. 

Three to five years from now, I expect a better economy than we have right now. I expect EPS to exceed $5 at that time. If people are more bullish then, a P/E multiple of 10 would see a price of $50 for GNK. That’s not unfathomable considering the high of $84.51 in May 2008 (more than 29 times 2008 earnings). I know that was during the commodity boom, but I’m only asking for a multiple of 10 instead of 29, which I believe is quite reasonable. A multiple of 12-15 is still not unthinkable and would put it in line for considerably more than a triple from the current level.

I believe GNK is both a solid short-term and long-term play. Both profitable and unprofitable drybulk shippers have been slammed with the recent slump in the BDI. I expect a short-term bounce of 20% to 50% and a possible triple or more within 5 years. Management has done a good job with fleet utilization, achieving almost 100% as of Q1 2010. The growth is quite aggressive, but I believe the acquisitions will contribute nicely to future earnings as long as the debt level is contained.

Suffice to say we believe this might not only be a long time play but also a solid short term one.  Keep tabs on our investment highlights on Twitter and look for new stock commentary on our internet channel.  For more information about GNK click this link. 

With the help of our Fool peers here is a quick look at the stocks making it into Warren Buffet’s portfolio.

When it comes to investing, there’s a heck of a lot that Buffett can do that I simply can’t. For instance, back in the fear-filled days of 2008, he wrangled preferred stock yielding 10% from both Goldman Sachs and General Electric (NYSE: GE). He’s also been able to snatch up great privately held companies like See’s Candies and swallow whole public companies such as Burlington Northern Santa Fe. Such is the benefit of a sterling reputation, an eye for bargains, and a massive balance sheet.

But when it comes to common stocks, I can go after the exact same shares that Buffett is buying for Berkshire. And when it comes to one stock in particular, I am most definitely on the same page as Buffett. It’s Berkshire’s largest stock holding. It’s a staple among consumer staples. It is, of course, Coca-Cola (NYSE: KO).

Here are some similar stocks like Coca-Cola that we agree have the merits for us to buy and hold on to. 

1. Altria (NYSE: MO) and Philip Morris International (NYSE: PM) may leave a bad taste in some investors’ mouths (no pun intended) since their business is slinging tobacco products. But as far as finding a business with a rock star of a product at its core, these two companies may out-Coke Coke. In the U.S. the Marlboro brand commands an amazing 42% of the cigarette market, and internationally it’s been the top brand since 1972. Marlboro’s 302 billion cigarettes sold internationally in 2009 beat the next three competitors combined.
2. Diageo (NYSE: DEO) could likewise be categorized as “sin stock,” but I’d prefer to categorize it as simply sinfully successful. Just as nothing needs to be done to keep the Coke product successful, Diageo doesn’t need to do much to keep leading brands like Smirnoff, Johnnie Walker, Guinness, Captain Morgan, and Jose Cuervo — to name a few — trucking along. Motley Fool Income Investor advisor James Early recently made Diageo his pick for The Motley Fool’s “11 O’Clock Stock” series, largely because of its amazing brand portfolio.
3. Procter & Gamble (NYSE: PG) doesn’t have a single product that provides the foundation of the company, but instead it has large portfolio of products. P&G does more tweaking to its products than Coke — think about the changes to Gillette razors or innovations for Pampers diapers — but brands like Tide, Vicks, Oral-B, Scope, Zest, and Old Spice don’t need significant technological advancements to keep the dollars rolling in.

Join us and the other Fools and share your tips! 

At the Daily Tape we look for opportunities in the market this includes short term plays as well as those that produce the best dividends for your money.  We follow the best traders and investment commentary out there for one main reason, to make us the most money possible and to offer this information to our readers.

Thanks to Fool commentary we want to share with you the best dividend stocks out there.

Don’t be fooled into thinking dividend stocks are just for those nearing retirement, though. For fans of growth stocks, a study by Robert Arnott and Clifford Asness actually links higher dividend payouts to higher earnings growth. Further, Wharton professor Jeremy Siegel has studied the dividend situation and concludes: “Through the years, diversified portfolios of stocks that pay dividends have not only beaten those that don’t, but have also handily outperformed the S&P 500.”

So what are the biggest payers? 

For those looking for some of these dividend plays, Standard & Poor’s helps us out. Each year, they construct a list called the Dividend Aristocrats. These are “large cap, blue chip companies within the S&P 500 that have followed a policy of increasing dividends every year for at least 25 consecutive years.”

Yes, you read that right. 25 years.

Only a few dozen companies make the list. Here are the seven with the highest dividend yields.